[New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment].
作者信息
Tauveron-Jalenques Urbain, Bay Jacques-Olivier
机构信息
CHU Clermont-Ferrand, site Estaing, service de thérapie cellulaire et d'hématologie clinique adulte, 63100 Clermont-Ferrand, France.
CHU Clermont-Ferrand, site Estaing, service de thérapie cellulaire et d'hématologie clinique adulte, 63100 Clermont-Ferrand, France; Université d'Auvergne, EA7453 CHELTER, 63000 Clermont-Ferrand, France.
出版信息
Bull Cancer. 2023 May;110(5):476-477. doi: 10.1016/j.bulcan.2023.02.014. Epub 2023 Mar 21.
PMID:36949000
Abstract
摘要
相似文献
1
[New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment].[新药批准：loncastuximab tesirine用于经两线治疗后复发/难治性弥漫性大B细胞淋巴瘤]
Bull Cancer. 2023 May;110(5):476-477. doi: 10.1016/j.bulcan.2023.02.014. Epub 2023 Mar 21.
2
Loncastuximab Tesirine: First Approval.朗斯妥昔单抗：首次获批。
Drugs. 2021 Jul;81(10):1229-1233. doi: 10.1007/s40265-021-01550-w.
3
Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.洛卡妥昔单抗：一种治疗复发或难治性弥漫性大B细胞淋巴瘤的有效疗法。
Eur J Clin Pharmacol. 2022 May;78(5):707-719. doi: 10.1007/s00228-021-03253-3. Epub 2022 Jan 21.
4
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Loncastuximab tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤（LOTIS-2）：一项多中心、开放标签、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11.
5
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.评估 loncastuximab tesirine 注射液治疗复发或难治性大 B 细胞淋巴瘤成人患者的疗效和安全性。
Expert Rev Anticancer Ther. 2021 Dec;21(12):1313-1320. doi: 10.1080/14737140.2021.1988853. Epub 2021 Oct 17.
6
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.抗 CD19 单克隆抗体治疗复发或难治性 B 细胞恶性肿瘤：以弥漫性大 B 细胞淋巴瘤为重点的叙述性综述。
J Cancer Res Clin Oncol. 2022 Jan;148(1):177-190. doi: 10.1007/s00432-021-03833-x. Epub 2021 Nov 6.
7
[Epcoritamab - relapsed or refractory large diffuse B cells lymphoma after two or more lines of systemic therapy].[依泊妥单抗 - 用于接受过两线或更多线全身治疗后的复发或难治性大B细胞淋巴瘤]
Bull Cancer. 2024 Jun;111(6):544-545. doi: 10.1016/j.bulcan.2024.02.011. Epub 2024 Apr 16.
8
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.Loncastuximab tesirine 用于治疗复发或难治性弥漫性大 B 细胞淋巴瘤。
Expert Opin Biol Ther. 2021 Nov;21(11):1373-1381. doi: 10.1080/14712598.2021.1973998. Epub 2021 Sep 10.
9
Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Loncastuximab Tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤。
Int J Mol Sci. 2024 Jul 10;25(14):7580. doi: 10.3390/ijms25147580.
10
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.抗体药物偶联物 loncastuximab tesirine 治疗弥漫性大 B 细胞淋巴瘤。
Blood. 2022 Jul 28;140(4):303-308. doi: 10.1182/blood.2021014663.
Zotero 插件